Safety and Feasibility of Fasting While Receiving Chemotherapy

This study has been completed.
Sponsor:
Information provided by:
King Fahad Medical City
ClinicalTrials.gov Identifier:
NCT00757094
First received: September 19, 2008
Last updated: February 24, 2010
Last verified: February 2010
  Purpose

Fasting (refraining from eating and drinking) during the day is safe while receiving chemotherapy.


Condition
Fasting
Chemotherapy
Cancer

Study Type: Observational
Study Design: Observational Model: Case-Crossover
Time Perspective: Prospective
Official Title: Safety and Feasibility of Fasting While Receiving Chemotherapy

Further study details as provided by King Fahad Medical City:

Primary Outcome Measures:
  • Safety of fasting while receiving chemotherapy [ Time Frame: two months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Effect of fasting on chemotherapy side effects [ Time Frame: two months ] [ Designated as safety issue: No ]

Enrollment: 12
Study Start Date: September 2008
Study Completion Date: March 2009
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts
I
Patients planning to observe fasting while receiving chemotherapy during the month of Ramadan

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Fasting patients who are schedulled to receive chemotherapy during the month of Ramadan

Criteria

Inclusion Criteria:

  • Age > 18 years
  • Established diagnosis of cancer
  • Signed informed consent
  • Adequate CBC and chemistry to receive chemotherapy

Exclusion Criteria:

  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00757094

Locations
Saudi Arabia
King Fahad Medical City
Riyadh, Saudi Arabia, 11525
Sponsors and Collaborators
King Fahad Medical City
Investigators
Principal Investigator: Ali SM Al-Shanqeeti, MD King Fahad Medical City